Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
 logo final copy.png)
The Hippocratic Editorial and VT team. Please send your suggestions to [email protected]
Latest posts by Hippocratic Post (see all)
- Combination of drugs could prevent thousands of heart attacks - 21st April 2025
- UQ Study Links Poor Teen Diets to Heavy Social Media Use - 21st April 2025
- Gut microbiome could delay onset of type 1 diabetes - 3rd April 2025
